PRAX Stock Cash Flow Statements

Praxis Precision Medicines Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Praxis Precision Medicines Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31

cash flows from operating activities:
net income	-71,127,000	-69,296,000	-58,679,000	-51,910,000	-32,677,000	-39,553,000	-26,878,000	-24,632,000	-34,312,000	-37,455,000	-41,173,000	-43,945,000	-60,194,000	-68,717,000	-58,582,000	-44,705,000	-36,401,000	-27,373,000	-25,706,000
adjustments to reconcile net income to net cash from operating activities:
depreciation expense	46,000	47,000	47,000	92,000	107,000	112,000	111,000	109,000	106,000	106,000	105,000	102,000	119,000	93,000	93,000	39,000	27,000	23,000	20,000
stock-based compensation expense	7,770,000	8,786,000	8,575,000	12,432,000	5,878,000	14,475,000	5,726,000	5,763,000	5,775,000	7,593,000	6,366,000	6,730,000	7,611,000	7,886,000	6,106,000	6,521,000	5,400,000	4,666,000	3,826,000
non-cash operating lease expense	257,000	249,000	243,000	236,000	230,000	224,000	218,000	212,000	206,000	201,000	196,000	190,000	186,000	180,000	470,000	467,000	292,000	183,000	179,000
amortization of premiums and discounts on marketable securities	-987,000	-1,229,000	-1,390,000	-2,005,000	-1,531,000	-84,000	0	0	2,000	45,000	196,000	209,000	223,000	375,000	633,000	639,000	554,000	261,000
non-cash collaboration and license agreement expense			0	0	0	2,500,000
changes in operating assets and liabilities:
prepaid expenses and other current assets	280,000	6,637,000	-8,789,000	1,821,000	-449,000	-808,000	-1,337,000	3,287,000	3,051,000	1,771,000	-1,779,000	1,604,000	1,783,000	-1,061,000	-6,529,000	4,280,000	-1,496,000	-2,035,000	-4,039,000
accounts payable	5,923,000	10,381,000	-2,482,000	7,006,000	-1,400,000	3,589,000	-1,299,000	-894,000	-8,976,000	2,314,000	4,550,000	-1,699,000	-1,448,000	2,489,000	3,236,000	323,000	1,500,000	2,208,000	416,000
accrued expenses	3,474,000	-8,280,000	8,105,000	5,412,000	3,201,000	-608,000	374,000	-6,338,000	3,965,000	-6,498,000	-2,034,000	-7,884,000	-5,163,000	4,616,000	9,969,000	8,587,000	371,000	-3,477,000	5,248,000
operating lease liabilities	-311,000	-303,000	-291,000	-286,000	-278,000	-271,000	-261,000	-254,000	-250,000	-240,000	-233,000	-226,000	-326,000	-26,000	-197,000	-193,000	-188,000	-185,000	-181,000
deferred revenue			-1,463,000	-301,000	-358,000	-431,000	-515,000	-468,000	-781,000	-683,000
other	-1,000	-2,000			-1,000	-2,000					0	0	0	56,000	-56,000	80,000	-72,000	7,000
net cash from operating activities	-54,676,000	-53,010,000	-56,122,000	-27,500,000	-27,278,000	-20,857,000	-23,861,000	-23,215,000	-31,214,000	-32,846,000	-28,806,000	-44,919,000	-57,209,000	-54,109,000	-44,857,000	-23,962,000	-30,013,000	-25,722,000	-20,228,000
capex	0	64,000	0	0	0	0	0	0	0	0	0	-45,000	-110,000	-289,000	-531,000	-450,000	-65,000	47,000	0
free cash flows	-54,676,000	-52,946,000	-56,122,000	-27,500,000	-27,278,000	-20,857,000	-23,861,000	-23,215,000	-31,214,000	-32,846,000	-28,806,000	-44,964,000	-57,319,000	-54,398,000	-45,388,000	-24,412,000	-30,078,000	-25,675,000	-20,228,000
cash flows from investing activities:
purchases of property and equipment											0	-45,000	-110,000	-289,000	-531,000	-450,000	-65,000	-4,000
purchases of marketable securities	-41,347,000	-117,057,000	-69,418,000	-11,959,000	-198,922,000	-91,220,000					0	0	0	-83,022,000	0	0	-24,164,000	-140,006,000
maturities of marketable securities	59,297,000	65,993,000	58,500,000	61,525,000			0	0	5,000,000	34,000,000	22,594,000	48,000,000	35,000,000	74,761,000	10,700,000
net cash from investing activities	17,894,000	-51,064,000	-10,918,000	49,566,000	-195,922,000	-91,220,000	-50,000	0	5,000,000	34,000,000	22,594,000			-8,550,000	10,169,000	13,550,000	-24,229,000	-140,010,000
cash flows from financing activities:
issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs			0	-108,000	216,095,000	161,649,000	0	0
issuance of common stock from collaboration and license agreement			0	0	0	14,765,000
proceeds from at-the-market offerings, net of issuance and commission costs	28,359,000	54,904,000	111,950,000	1,344,000	-34,000	6,337,000
payments of tax withholdings related to vesting of restricted stock units	-23,000	-1,195,000	-157,000	-1,000	-13,000	-137,000	-5,000	-1,000	-4,000	-127,000	-7,000	-7,000	-16,000	-230,000
proceeds from exercise of stock options and employee stock purchase plan purchases				201,000	315,000	143,000		1,000
net cash from financing activities	28,630,000	54,269,000	113,767,000	1,436,000	216,363,000	182,757,000	4,126,000	0	69,675,000	18,070,000	5,387,000	3,365,000	504,000	1,209,000	7,713,000	212,000	99,385,000	276,000	202,064,000
increase in cash, cash equivalents and restricted cash	-8,152,000	-49,805,000	46,727,000	23,502,000	-6,837,000	70,680,000	-19,785,000	-23,215,000	43,461,000	19,224,000									181,836,000
cash, cash equivalents and restricted cash, beginning of period	0	215,788,000	0	0	0	81,716,000	0	0	0	62,031,000	0	0	0	139,720,000	0	0	0	297,208,000	0
cash, cash equivalents and restricted cash, end of period	-8,152,000	165,983,000	46,727,000	23,502,000	-6,837,000	152,396,000	-19,785,000	-23,215,000	43,461,000	81,255,000	-825,000	6,401,000	-21,815,000	78,270,000	-26,975,000	-10,200,000	45,143,000	131,752,000	181,836,000
reconciliation of cash, cash equivalents and restricted cash:
cash and cash equivalents	-8,152,000	165,567,000	46,727,000	23,502,000	-6,837,000	151,980,000	-19,785,000	-23,215,000	43,461,000	80,839,000	-825,000	6,401,000	-21,815,000	77,854,000	-26,975,000	-10,200,000	44,727,000	131,152,000
restricted cash	0	416,000	0	0	0	416,000	0	0	0	416,000	0	0	0	416,000	0	0	416,000	600,000
total cash, cash equivalents and restricted cash	-8,152,000	165,983,000	46,727,000	23,502,000	-6,837,000	152,396,000	-19,785,000	-23,215,000	43,461,000	81,255,000	-825,000	6,401,000	-21,815,000	78,270,000	-26,975,000	-10,200,000	45,143,000	131,752,000
supplemental disclosures of non-cash activities:
purchase of property and equipment included in accrued expenses	0	64,000
issuance costs from at-the-market offering included in accounts payable and accrued expenses
offering costs from follow-on offering included in accounts payable
proceeds from exercise of stock options		560,000								101,000
issuance costs from at-the-market offering included in accrued expenses						168,000
proceeds from exercise of options and employee stock purchase plan purchases
issuance costs from at-the-market offerings included in accrued expenses
offering costs from follow-on public offering included in accounts payable							0
purchases of property and equipment included in accounts payable
proceeds from at-the-market offerings, net of issuance costs							4,025,000	0	6,032,000	18,096,000	5,231,000	2,962,000	0	1,368,000
payment of issuance costs for at-the-market offerings
offering costs included in accrued expenses
proceeds from follow-on public offering, net of issuance costs															-67,000	-96,000
payment of issuance costs for at-the-market offerings and initial public offering											0	0	0	-262,000
proceeds from exercise of options and employee stock purchase plan contributions											163,000	410,000
decrease in cash, cash equivalents and restricted cash											-825,000	6,401,000	-21,815,000	-61,450,000		-10,200,000	45,143,000	-165,456,000
operating lease right-of-use assets obtained in exchange for operating lease liabilities															0	0
purchases of property and equipment included in accrued expenses
net cash provided (used) in investing activities
offering costs included in accounts payable and accrued expenses
proceeds from exercise of options to purchase common stock														333,000	479,000	308,000	809,000	851,000	61,000
purchases of property and equipment included in accrued expenses and accounts payable
proceeds from initial public offering of common stock, net of issuance costs
payment of issuance costs for initial public offering
proceeds from issuance of redeemable convertible preferred stock, net of issuance costs																			0
repurchase of series c redeemable convertible preferred stock																			0
purchases of property and equipment included in accounts payable and accrued expenses
accretion of redeemable convertible preferred stock to redemption value																			950,000
payment of issuance costs for initial public offering and issuance of redeemable convertible preferred stock																0
deferred offering costs included in accrued expenses
deferred offering costs included in accounts payable and accrued expenses																			-350,000
payment of deferred offering costs																		-575,000
purchases of property, plant and equipment included in accounts payable																		51,000
redeemable convertible preferred stock issuance costs included in accounts payable
other non-current assets
operating lease liabilities recorded upon adoption of asc 842

We provide you with 20 years of cash flow statements for Praxis Precision Medicines stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Praxis Precision Medicines stock. Explore the full financial landscape of Praxis Precision Medicines stock with our expertly curated income statements.

The information provided in this report about Praxis Precision Medicines stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.